Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) shares traded down 6.7% during trading on Monday . The stock traded as low as $40.00 and last traded at $41.73. 13,166 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 204,032 shares. The stock had previously closed at $44.74.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded Jyong Biotech to a "hold" rating in a report on Monday, June 30th.
View Our Latest Analysis on Jyong Biotech
Jyong Biotech Price Performance
Jyong Biotech Company Profile
(
Get Free Report)
OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.
Read More
Before you consider Jyong Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jyong Biotech wasn't on the list.
While Jyong Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
